BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $20,683,000 | -24.1% | 441,288 | -1.3% | 0.01% | -25.0% |
| Q2 2021 | $27,257,000 | -1.3% | 447,132 | -0.3% | 0.01% | 0.0% |
| Q1 2021 | $27,622,000 | -8.2% | 448,417 | +6.0% | 0.01% | -20.0% |
| Q4 2020 | $30,075,000 | +93.1% | 422,936 | +1.9% | 0.01% | +66.7% |
| Q3 2020 | $15,575,000 | +12.3% | 415,125 | -2.4% | 0.01% | +20.0% |
| Q2 2020 | $13,870,000 | +21.8% | 425,321 | +8.3% | 0.01% | 0.0% |
| Q1 2020 | $11,389,000 | +3.5% | 392,708 | +25.1% | 0.01% | +25.0% |
| Q4 2019 | $11,004,000 | +63.3% | 313,954 | +0.0% | 0.00% | +33.3% |
| Q3 2019 | $6,739,000 | -28.6% | 313,858 | -10.3% | 0.00% | -25.0% |
| Q2 2019 | $9,440,000 | – | 350,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |